ESPL1 and breast cancer: Consistent with these observations, expression profiling demonstrated that ESPL1, E2F8, and MKI67 were overexpressed across BC stages, while ESR1 and PGR were downregulated, particularly in more aggressive or hormone receptor-negative subtypes.